Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Exclusion Criteria

• •Treatment of psoriasis with biologic agents within 90 days prior to Baseline assessment and during the study.
• •Treatment with methotrexate, cyclosporine, retinoids, hydroxyurea or other systemic agents within 30 days prior to Baseline assessment and during the study.
• •Phototherapy within 30 days prior to Baseline assessment and during the study.
• •Psoriasis topical therapy within 14 days prior to Baseline assessment and during the study (exception: non-medicated emollients and tar shampoo will be allowed).
• •History of liver disease or abnormal liver enzymes
• •Serum creatinine ≥1.5 times the upper limit of normal for age and sex-matched controls.
• •Previous treatment with Apo805K1or Thymodepressin or other immunosuppressant drugs.
• •Evidence of skin conditions other than psoriasis (e.g., eczema) that could interfere with psoriasis assessments.
• •History of chronic infection or malignancy